Market Research Logo
Publisher: FirstWord
Category: Pharmaceuticals

Pharmaceuticals market research reports by FirstWord

(451 reports matching your criteria)
  • Review of Influence: The Institute for Clinical and Economic Review (ICER)

    ... novel and inclusive work on the value of drugs, using its own value framework and assessing the affordability, and even going so far as setting the value-based price benchmark of new drugs, has given payers ... Read More

  • Time to Market: Accelerating Market Access

    ... need to know the options and consider the wider implications. The options for faster market access multiplied in the last three years, with new opportunities available both before and after regulatory approval, as well as ... Read More

  • The State of Pharma Digital Transformation

    ... How culturally ready is the industry for the lightning-fast pace of technology? Our professional researchers carried out a deep dive into the current state of pharma digital transformation to find out if and how digital ... Read More

  • Pharma-Tech Partnerships: Key Success Factors

    ... the drug development process and patient journey, pharma needs to quickly build technology-driven capabilities. It can't do this alone, and tech partnerships offer a way forward. But for technology partnerships to reach their full potential ... Read More

  • Duchenne Muscular Dystrophy: KOL Insight [2018]

    ... known cure and few treatment options. Since 2014, two antisense oligonucleotide therapies [Exondys 51 (Sarepta Therapeutics) and Translarna (PTC Therapeutics)] have been approved but how are they faring on the market? Find out how key ... Read More

  • Succeeding with value based contracts

    ... the agenda in pharma boardrooms across the US and Europe–and some early-adopters are reaping the rewards. The terminology might vary, but without question interest in this type of agreement is higher than ever. Why now? ... Read More

  • Orphan Drug Commercial Models: Strategies for Success

    ... orphan drug ambitions. Success hinges on ever closer relationships with patients, HCPs and KOLs to create therapy awareness, conduct research and build evidence of value. But what are the patient engagement, market access and pricing ... Read More

  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]

    ... 3-5 years. Four late-stage pipeline programmes are advancing through development, and 16 mid-stage pipeline programmes are also making progress. Which ones will pass muster? And which ones do leading key opinion leaders (KOLs) believe will ... Read More

  • Medical Affairs Reputations: Multiple Sclerosis (EU5) 2018

    ... way in terms of interaction frequency and overall quality of interactions, but there’s room for improvement in other areas. The 150 neurologists from the EU5 markets (France, Germany, Italy, Spain and the UK) we polled ... Read More

  • Market Access Impact: Chronic Lymphocytic Leukaemia (EU5) 2018

    ... for chronic lymphocytic leukaemia (CLL) treatments in Europe, and certain brands are losing out on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the ... Read More

  • Breast Cancer: KOL Insight [2018]

    ... is expected to fare after years of Herceptin domination in the HER2-positive space. KOLs discuss how Roche’s Perjeta will be used in the future and whether the APHINITY trial results will change prescribing habits. Experts ... Read More

  • New Commercial Models: Benchmarking Pharma Companies [2018]

    ... are these new commercial models proving to be? Customer first or an alternative stakeholder centric model? Focus on agility or take time on engagement? Push hard on digital or build a hybrid commercial approach? There ... Read More

  • Medical Affairs Reputations: Multiple Sclerosis (US) 2018

    ... the way in terms of interaction frequency and overall quality of interactions, but there’s room for improvement in other areas. The 100 neurologists we polled provide insights on several medical affairs teams, and opinions are ... Read More

  • Market Access Impact: Chronic Lymphocytic Leukaemia (US) 2018

    ... prescriptions for chronic lymphocytic leukaemia (CLL) treatments in the US, and certain brands are losing out on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to ... Read More

  • Market Access Impact: Haemophilia A (EU5) 2018

    ... A prescriptions in Europe, and certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access ... Read More

  • Market Access Impact: Haemophilia A (US) 2018

    ... haemophilia A prescriptions in the US, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market ... Read More

  • Market Access Impact: Renal Cell Carcinoma (US) 2018

    ... all renal cell carcinoma (RCC) prescriptions in the US, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing ... Read More

  • Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]

    ... biologics and new MOAs as the COPD treatment landscape continues to evolve. Of the key companies currently competing in this space -- AstraZeneca, Boehringer Ingelheim, GSK and Novartis -- which companies do key opinion leaders ... Read More

  • Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

    ... IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial ... Read More

  • Psoriasis: Update Bulletin #3 [April 2018]

    ... from two pivotal Phase III trials with interleukin-23 (IL-23) inhibitor risankizumab, including head-to-head data with competitor Stelara (ustekinumab; Janssen Biotech); KOL views on the Food and Drug Administration’s (FDA) approval of second-in-class interleukin-23 (IL-23) inhibitor ... Read More

  • Prostate Cancer: Update Bulletin #2 [April 2018]

    ... of Johnson & Johnson’s (J&J’s) next-generation androgen receptor inhibitor Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC), data published from the PROSPER study for Pfizer/Astellas’ Xtandi (enzalutamide) in the non-metastatic CRPC population and ... Read More

  • Biosimilars: US Payer Perspectives (2018)

    ... as a solution to stem the tide of soaring drug spending, in the cold light of day, the US biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of endless litigation ... Read More

  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]

    ... cell therapies in two types of blood cancer. Find out how these novel treatments are impacting treatment choices so far and how their introduction is progressing in the US. Eight of the world’s leading key ... Read More

  • Medical Affairs in Emerging Markets

    ... becoming increasingly complex with developments, such as the increasing use evidence-based prescribing, putting medical affairs (MA) teams under pressure. But in BRIC countries a one size fits all approach to MA will not cater for ... Read More

  • Market Access Impact: Renal Cell Carcinoma (EU5) 2018

    ... cell carcinoma (RCC) prescriptions in Europe, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market ... Read More

< prev 1 3 4 5 6 7 8 9 10